International Journal of Public Health and Medical Research
ISSN: 3006-7707 (Print), ISSN: 3006-3752 (Online) | Volume 3, Number 1, Year 2025
DOI: https://doi.org/10.62051/ijphmr.v3n1.02
Journal homepage: https://wepub.org/index.php/IJPHMR/index

The Impact of Diabetes on Cognitive Performance: A Comprehensive Review

Xudong Zhou

Guangxi University, Nanning, 530000, China

ABSTRACT

Diabetes Mellitus, a prevalent metabolic disorder, is increasingly acknowledged as a critical determinant of cognitive impairment. This comprehensive review synthesizes the current understanding of the pathophysiological mechanisms underlying cognitive deficits in diabetic individuals. It explores the contributions of chronic hyperglycemia, microvascular pathology, impaired insulin signaling, oxidative stress, and neuroinflammation as key drivers of neuronal injury and cognitive decline. And then the review delineates a range of risk factors—including advanced age, inadequate glycemic control, hypertension, and dyslipidemia—that exacerbate susceptibility to cognitive dysfunction in this patient population. The utility of advanced neuroimaging techniques and neuropsychological assessments in the detection and monitoring of cognitive changes is rigorously evaluated. Additionally, the article examines emerging preventive and therapeutic strategies, such as rigorous blood glucose control, management of cardiovascular risk factors, administration of antioxidants and anti-inflammatory agents, neuroprotective interventions, and psychological support. The review concludes with a discussion of its clinical relevance, underscoring the necessity for timely diagnosis and integrated management approaches to mitigate the cognitive burden of diabetes, and suggests avenues for future research aimed at addressing current knowledge voids and improving patient outcomes.

KEYWORDS

Diabetes; Cognitive Dysfunction; Neuroimaging Techniques; Glycemic Control; Therapeutic Interventions

1. INTRODUCTION

The global burden of Diabetes Mellitus (DM) has reached staggering proportions, with the World Health Organization estimating that the number of people living with diabetes has tripled since 1980. In 2019, the global prevalence stood at approximately 463 million individuals, and projections suggest that this figure could rise to over 700 million by 2045 (IDF, 2019) [1]. This exponential growth is not merely a statistical curiosity but a critical public health concern that poses a significant threat to global health systems. Diabetes is a precursor to a host of complications, including cardiovascular disease, nephropathy, retinopathy, and neuropathy, which collectively contribute to the morbidity, mortality, and economic burden associated with the condition [2].

Amidst this landscape, cognitive dysfunction has emerged as a less overt but equally devastating complication of DM. The prevalence of cognitive impairment in diabetic patients is remarkably high, with studies indicating that individuals with diabetes have a 1.5 to 2.5 times greater risk of developing cognitive decline compared to those without the disease [3]. Cognitive dysfunction in diabetes can manifest as mild cognitive impairment, executive dysfunction, or even Alzheimer's disease and other forms of dementia [4]. The impact of such impairments is multifaceted, affecting not only the quality

of life for patients and their caregivers but also the ability to self-manage the complex demands of diabetes care, potentially leading to worsening glycemic control and an increased risk of complications.

The purpose of this review is to provide a comprehensive synthesis of the current understanding of cognitive dysfunction in DM, its epidemiology, underlying mechanisms, and clinical implications. The structure of this article is as follows: We delve into the prevalence and clinical correlates of cognitive dysfunction in diabetic patients, highlighting the magnitude of the problem. Subsequent sections explore the pathophysiological links between DM and cognitive impairment, risk factors that exacerbate this association, and the state of diagnostic and therapeutic strategies. We conclude by summarizing the key findings and proposing directions for future research that could lead to improved patient care and outcomes. It is our hope that this synthesis will contribute to the development of targeted interventions that can mitigate the cognitive burden of diabetes and enhance the quality of life for those affected.

2. THE ASSOCIATION BETWEEN DIABETES MELLITUS AND COGNITIVE DYSFUNCTION

2.1. Pathophysiological Characteristics of Diabetes Mellitus

Diabetes Mellitus is a long-standing metabolic condition marked by high blood sugar levels, stemming from impairments in insulin production, its effectiveness, or a combination of these factors [5]. The pathophysiology of DM is multifaceted and involves several interconnected pathways that contribute to the development of cognitive dysfunction. Insulin Signaling and Neurodegeneration: insulin signaling plays a crucial role in brain function, including glucose metabolism, neurogenesis, and synaptic plasticity [6]. In DM, impaired insulin signaling in the brain can lead to neurodegenerative changes [7], such as amyloid deposition and tau hyperphosphorylation, which are reminiscent of Alzheimer's disease pathology [8]. Chronic Hyperglycemia and Vascular Dysfunction: Prolonged hyperglycemia induces oxidative stress [9], inflammation [10], and endothelial dysfunction [11], leading to microvascular and macrovascular complications. These alterations in cerebral blood flow and vessel integrity can impair cognitive function [12]. Advanced Glycation End Products (AGEs): The accumulation of AGEs, resulting from non-enzymatic glycation of proteins and lipids, can cross-link brain extracellular matrix proteins and neuronal receptors, disrupting neural signaling and contributing to cognitive impairment [13]. Dyslipidemia and Neuroinflammation: Elevated triglycerides and low-density lipoprotein cholesterol, common in DM, can lead to neuroinflammation and further exacerbate neuronal damage [14].

2.2. Definition and Classification of Cognitive Dysfunction

Cognitive dysfunction refers to an acquired deficit in cognitive abilities, including memory, attention, language, executive functions, and visuospatial skills. In the context of DM, the classification of cognitive dysfunction includes: Mild Cognitive Impairment (MCI) represents an intermediate phase between typical age-related cognitive decline and dementia, featuring subjective memory concerns along with measurable cognitive deficits that do not notably disrupt everyday functioning [15]. Dementia refers to a persistent or advancing deterioration in mental capabilities that is profound enough to disrupt routine activities of daily living [16]. In DM, the most common forms of dementia are Alzheimer's disease and vascular dementia [17]. Executive Dysfunction: This refers to a specific impairment in higher-order cognitive processes such as planning, organizing, multitasking, and problem-solving, which are particularly affected in diabetic patients.

2.3. Epidemiological Evidence of the Association Between DM and Cognitive Dysfunction

A substantial body of epidemiological research supports the association between DM and cognitive dysfunction: Prevalence Studies: Multiple cross-sectional and longitudinal studies [18, 19] have reported a higher prevalence of MCI and dementia in individuals with DM compared to non-diabetic controls. The prevalence rates vary but consistently show an increased risk ranging from 1.5 to 2.5 times. Cohort Studies: Comprehensive cohort investigations, including the Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation (ADVANCE) and the Diabetes Heart Study, have demonstrated that Diabetes Mellitus is linked to an expedited reduction in cognitive function over the course of time [20]. Meta-Analyses: Systematic reviews and meta-analyses have confirmed the robust association between DM and cognitive impairment, with some studies suggesting that the risk is independent of vascular disease [21]. Potential Confounders: Epidemiological studies have controlled for various confounders, including age, education, smoking, and cardiovascular disease, to establish a direct link between DM and cognitive dysfunction.

In conclusion, the association between DM and cognitive dysfunction is supported by robust pathophysiological, definitional, and epidemiological evidence. This evidence underscores the need for further research to elucidate the precise mechanisms and to develop preventive and therapeutic strategies to mitigate the cognitive burden of DM.

3. PATHOLOGICAL MECHANISMS OF COGNITIVE DYSFUNCTION IN DIABETES MELLITUS

The cognitive deficits observed in individuals with Diabetes Mellitus (DM) are the result of complex pathological mechanisms that intertwine to affect brain structure and function. This section delves into the impact of chronic hyperglycemia on the brain, focusing on microvascular changes, abnormalities in insulin signaling, and the interplay of oxidative stress and inflammation.

3.1. Microvascular Lesions

Chronic hyperglycemia is a hallmark of DM and leads to microvascular lesions, which are pivotal in the pathogenesis of diabetic cognitive impairment [22]. The subsequent microvascular alterations are of particular significance: Capillary rarefaction—extended periods of hyperglycemia trigger the impairment and apoptosis of endothelial cells, leading to a reduction in capillary density [23]. This reduction in capillary density impairs cerebral blood flow, leading to hypoxia and ischemia, which are detrimental to neuronal health and cognitive function. Basement membrane thickening: The accumulation of advanced glycation end products (AGEs) and extracellular matrix proteins causes thickening of the basement membrane, which hampers the exchange of nutrients and waste products between the blood and the brain parenchyma [24]. Endothelial cell dysfunction: Endothelial cells regulate vascular tone, inflammation, and coagulation. In DM, their dysfunction contributes to altered blood-brain barrier (BBB) permeability [25], allowing for the influx of harmful substances and the recruitment of immune cells, which can lead to neuroinflammation.

3.2. Disruption of Insulin Signaling Pathways

Insulin signaling in the brain is crucial for various neurophysiological processes. In DM, the following disruptions occur:

Impaired insulin transport: Hyperglycemia and insulin resistance impair the transport of insulin through the BBB [26]. Reduced brain insulin levels affect the phosphorylation of insulin receptor substrates (IRSs), which are essential for neuronal survival and synaptic plasticity [27]. Mitochondrial dysfunction: Insulin signaling also regulates mitochondrial function. Imbalance in cellular regulation

results in reduced ATP synthesis, an uptick in reactive oxygen species (ROS) production, and mitochondria-driven apoptosis, all of which contribute to neuronal injury [28]. Deficits in neurotrophic support: Insulin-like Growth Factor 1 (IGF-1) and Brain-Derived Neurotrophic Factor (BDNF) play pivotal roles in neurogenesis and the maintenance of synaptic plasticity [29]. Insulin signaling abnormalities lead to reduced levels of these neurotrophic factors, further exacerbating cognitive decline.

3.3. Oxidative Stress and Inflammatory Response

The interplay between oxidative stress and inflammation is a pivotal mechanism underlying cognitive impairment in DM:

Oxidative stress: Chronic hyperglycemia increases the production of ROS, overwhelming the cellular antioxidant defense systems [30]. ROS lead to the oxidation of lipids, proteins, and DNA, resulting in cellular damage and apoptosis [31]. Within the brain, such processes may result in the build-up of amyloid-beta peptides and the development of neurofibrillary tangles, both of which are linked to a deterioration in cognitive abilities [32]. Inflammatory cascade: Elevated blood glucose levels and advanced glycation end-products (AGEs) stimulate the secretion of pro-inflammatory cytokines, including tumor necrosis factor-alpha (TNF-α) [33], interleukin-1β (IL-1β) [34], and interleukin-6 (IL-6) [35]. These cytokines can cross the BBB, activating microglia and leading to neuroinflammation. The chronic inflammatory state exacerbates oxidative stress and contributes to the degradation of neural tissue [36].

In essence, the pathophysiological underpinnings of cognitive impairment in DM are complex, with persistent hyperglycemia serving as a pivotal factor. The constellation of microvascular damage, impaired insulin signaling, and the interplay between oxidative stress and inflammation collectively fuel the neurodegenerative trajectory. Deciphering these mechanisms is vital for crafting strategic therapeutic approaches intended to avert or postpone cognitive deterioration in individuals with diabetes.

4. RISK FACTORS FOR COGNITIVE DYSFUNCTION IN DIABETES MELLITUS

4.1. Metabolic

Hypertension is a common comorbidity in diabetic patients and is independently associated with cognitive impairment. Chronic hypertension can lead to cerebrovascular damage, including arteriosclerosis and microvascular injury, which compromise cerebral perfusion and contribute to cognitive decline [37]. The endothelial dysfunction and oxidative stress associated with hypertension further exacerbate brain vulnerability in diabetic individuals [38]. Dyslipidemia Elevated levels of total cholesterol, low-density lipoprotein cholesterol (LDL-C), and triglycerides, as well as decreased high-density lipoprotein cholesterol (HDL-C), are metabolic risk factors for cognitive impairment in DM [39]. Dyslipidemia can lead to the accumulation of cholesterol in the brain, promoting amyloid plaque formation and neuroinflammation, which are detrimental to cognitive function [40]. Obesity, particularly central obesity, is a significant risk factor for cognitive dysfunction in DM. Adipose tissue functions as an endocrine gland, releasing adipokines like leptin and adiponectin, which have the capacity to influence brain activity. Elevated leptin and reduced adiponectin concentrations, commonly observed in obesity, correlate with insulin resistance, neuroinflammatory processes, and cognitive decline [41].

4.2. Lifestyle

A sedentary lifestyle is a recognized risk factor for cognitive decline in DM. Regular physical activity is associated with improved cardiovascular health, enhanced neuroplasticity, and increased levels of neurotrophic factors, all of which are beneficial for cognitive function. Conversely, physical inactivity is linked to increased oxidative stress, inflammation, and metabolic dysregulation [42]. Unhealthy Diet Poor dietary habits, such as a high intake of saturated fats, sugars, and processed foods, contribute to metabolic syndrome and insulin resistance, which are risk factors for cognitive impairment. A diet rich in antioxidants, omega-3 fatty acids, and fiber, such as the Mediterranean diet, has been shown to protect against cognitive decline in diabetic patients [43]. Smoking and Alcohol Consumption Tobacco smoking and excessive alcohol consumption are lifestyle factors that exacerbate cognitive dysfunction in DM. Smoking induces oxidative stress, inflammation, and endothelial dysfunction, while heavy alcohol intake can lead to direct neurotoxic effects and nutritional deficiencies, both of which impair cognitive function [44].

4.3. Psychosocial

Psychological disorders, particularly depression and anxiety, are prevalent in diabetic patients and are associated with an increased risk of cognitive impairment [45]. These conditions may contribute to cognitive decline through altered neuroplasticity, increased inflammation, and hypothalamic-pituitary-adrenal (HPA) axis dysregulation [46]. Insufficient Social Support Lack of social support can lead to chronic stress, which is detrimental to cognitive health. Social isolation and loneliness are associated with increased inflammation, HPA axis activation, and reduced cognitive stimulation, all of which can accelerate cognitive decline in diabetic individuals [47].

4.4. Pharmacological

The choice of diabetes medication can influence cognitive function. For example, some studies suggest that sulfonylureas and thiazolidinediones may have negative effects on cognition [48, 49], whereas metformin [50] and DPP-4 inhibitors [51] may be protective. The impact of newer classes of antidiabetic drugs on cognitive function remains an area of active research. Medications for Other Chronic Conditions Diabetic patients often require multiple medications for comorbid conditions, such as hypertension or dyslipidemia. Some of these medications, including certain antihypertensives and statins, have been associated with cognitive side effects, although the evidence is mixed. The polypharmacy commonly seen in this patient population can complicate the assessment of cognitive impairment risk.

In conclusion, the risk factors for cognitive dysfunction in DM are multifactorial and interrelated. Addressing these risk factors through lifestyle modifications, pharmacological interventions, and psychosocial support is essential for the prevention and management of cognitive decline in diabetic patients.

5. ASSESSMENT METHODS FOR COGNITIVE DYSFUNCTION IN DIABETES MELLITUS

The accurate assessment of cognitive dysfunction in individuals with Diabetes Mellitus (DM) is crucial for early detection, monitoring disease progression, and evaluating the efficacy of interventions. This section details the neuropsychological and imaging techniques commonly used in the assessment of cognitive impairment in diabetic patients.

5.1. Neuropsychological Assessment

5.1.1. Cognitive Function Scales

Cognitive function scales are widely used to evaluate the cognitive status of individuals with DM. These scales provide a standardized measure of cognitive performance across various domains [52]. The Montreal Cognitive Assessment (MoCA) is especially adept at detecting mild cognitive impairment and is frequently utilized among individuals with diabetes. In contrast, the Mini-Mental State Examination (MMSE) is another broadly applied assessment, yet it may be less proficient in identifying nuanced cognitive deficits [53]. The Diabetes-Specific Cognitive Assessment (DSCA) [54] has been developed to specifically target cognitive domains affected by DM, such as attention, executive function, and learning and memory.

5.1.2. Executive Function Tests

Diabetic patients frequently exhibit deficits in executive functions, encompassing planning, problem-solving, and cognitive adaptability. Assessments such as the Trail Making Test (TMT), Stroop Test, and Wisconsin Card Sorting Test (WCST) are instrumental in evaluating these complex cognitive abilities. The TMT gauges visual attention, mental agility, and processing velocity, whereas the Stroop Test evaluates inhibitory regulation and cognitive versatility. The WCST examines conceptualization, categorization, and set-shifting skills, offering a window into the functioning of the frontal lobes.

5.2. Imaging Assessment

5.2.1. Structural Magnetic Resonance Imaging (sMRI)

sMRI is a valuable tool for assessing the structural integrity of the brain in diabetic patients. It can detect atrophic changes, such as hippocampal sclerosis, which is associated with cognitive impairment. Voxel-based morphometry (VBM) is a commonly used sMRI technique that allows for the quantification of regional brain volumes and the identification of patterns of brain atrophy associated with DM-related cognitive decline [55].

5.2.2. Functional Magnetic Resonance Imaging (fMRI)

fMRI enables the investigation of brain function by measuring hemodynamic responses associated with neural activity. This technique is used to assess cognitive tasks and can reveal alterations in brain activation patterns in diabetic patients. fMRI studies have shown that individuals with DM may exhibit decreased activation in regions associated with memory and executive function during cognitive tasks, suggesting compensatory mechanisms or neural inefficiency [56].

5.2.3. Positron Emission Tomography (PET)

PET imaging is a powerful tool for assessing neurochemical changes in the brain. It can be used to measure glucose metabolism, which is often disrupted in DM, using fluorodeoxyglucose (FDG-PET). Decreased glucose metabolism in brain regions involved in cognition, such as the prefrontal cortex and hippocampus, has been associated with cognitive impairment in diabetic patients [57]. Additionally, amyloid-PET and tau-PET can be used to assess the presence of neurodegenerative pathology, which may contribute to cognitive decline [58].

In summary, the assessment of cognitive dysfunction in DM requires a multifaceted approach that combines neuropsychological testing with advanced imaging techniques. Each method provides unique insights into the cognitive status of diabetic patients, and the integration of these methods can enhance the sensitivity and specificity of cognitive impairment detection. The findings from these assessments are critical for guiding clinical management and research efforts aimed at developing interventions to prevent or delay cognitive decline in this population.

6. PREVENTION AND TREATMENT STRATEGIES FOR COGNITIVE DYSFUNCTION IN DIABETES MELLITUS

The management of cognitive dysfunction in Diabetes Mellitus (DM) is a multifaceted challenge that requires a comprehensive approach. This section outlines the strategies for prevention and treatment of cognitive impairment in diabetic patients, supported by empirical evidence from clinical studies.

6.1. Blood Glucose Control

6.1.1. Lifestyle Interventions

Lifestyle modifications are fundamental in the management of DM and the prevention of cognitive decline. Regular physical activity has been shown to improve glycemic control, reduce insulin resistance, and enhance cognitive function [59]. Exercise programs that combine aerobic, resistance, and flexibility training can be particularly beneficial [60]. Dietary interventions, such as the adoption of a Mediterranean-style diet rich in fruits, vegetables, whole grains, and omega-3 fatty acids, have been associated with better cognitive outcomes [61]. Weight management through caloric restriction and increased physical activity is also crucial, as obesity is a known risk factor for cognitive impairment.

6.1.2. Pharmacological Treatment

Optimal blood glucose control is essential to prevent cognitive decline. Various antidiabetic medications, including metformin, sulfonylureas, and insulin, are used to manage hyperglycemia. The choice of medication should be individualized, considering the patient's overall health, potential side effects, and the risk of hypoglycemia, which itself can be detrimental to cognitive function. Recent studies [62, 63] suggest that some antidiabetic drugs, like GLP-1 receptor agonists and SGLT2 inhibitors, may have neuroprotective effects, although more research is needed to confirm these findings.

6.2. Blood Pressure and Lipid Management

Hypertension and dyslipidemia frequently coexist with Diabetes Mellitus and each is independently linked to cognitive deficits. Treatments for hypertension, including ACE inhibitors, angiotensin receptor blockers, and calcium channel blockers, have demonstrated the potential to mitigate the risk of cognitive deterioration [64]. Statins and other lipid-lowering agents are used to manage hyperlipidemia and may also contribute to the preservation of cognitive function by reducing atherosclerosis and inflammation [65].

6.3. Antioxidants and Anti-inflammatory Treatments

Oxidative stress and inflammation play significant roles in the pathogenesis of cognitive impairment in DM. Antioxidants such as alpha-lipoic acid [66], vitamins E and C [67], and coenzyme Q10 [68] have been studied for their potential neuroprotective effects. Anti-inflammatory medications, encompassing nonsteroidal anti-inflammatory drugs (NSAIDs) as well as corticosteroids, are potential considerations. However, the data supporting their preventive effect on cognitive decline is inconsistent, and the potential hazards of prolonged administration must be meticulously evaluated [69].

6.4. Neuroprotective Agents

The development of neuroprotective agents specifically targeting cognitive impairment in DM is an area of active research. Drugs that modulate neurotransmitter systems, such as cholinesterase inhibitors used in Alzheimer's disease, are being explored for their potential benefits in diabetic

cognitive impairment [70]. Additionally, compounds that target specific pathways involved in neurodegeneration, such as those affecting amyloid-beta and tau pathology, are under investigation [71].

6.5. Psychological Interventions and Social Support

Psychological interventions, including cognitive training, cognitive-behavioral therapy, and mindfulness-based stress reduction, can improve cognitive function and psychological well-being in diabetic patients. Social support is also crucial, as loneliness and social isolation are risk factors for cognitive decline. Community-based programs and support groups can provide emotional and practical assistance, enhancing the patient's ability to manage their condition and potentially slowing cognitive decline.

In conclusion, the prevention and treatment of cognitive dysfunction in DM require a holistic approach that addresses metabolic control, vascular health, oxidative stress, inflammation, and psychological well-being. The strategies outlined here are based on current clinical evidence and provide a framework for healthcare professionals to intervene early and effectively in the management of cognitive impairment in diabetic patients. Future research should focus on the development of randomized controlled trials to further validate these interventions and to identify new therapeutic targets for cognitive preservation in DM.

7. CONCLUSION

The exploration of cognitive dysfunction within the context of Diabetes Mellitus (DM) has yielded pivotal insights that have significantly enhanced our comprehension of this intricate condition. Foremost, a robust correlation has been established between DM and an elevated likelihood of cognitive impairment, spanning a continuum from subtle cognitive deficits to the onset of full-blown dementia. Epidemiological research has consistently demonstrated that individuals with DM bear a 1.5 to 2.5 times greater risk of experiencing cognitive decline in comparison to their non-diabetic counterparts [3]. Additionally, the pathophysiological underpinnings of cognitive dysfunction in DM are complex and multifaceted, encompassing chronic hyperglycemia, microvascular lesions, disruptions in insulin signaling pathways, oxidative stress, inflammation, and neurodegenerative processes. These interwoven mechanisms contribute to cognitive deterioration through diverse pathways, including disrupted neuronal metabolism, compromised blood-brain barrier integrity, and synaptic degeneration. The evaluation of cognitive dysfunction in DM has been advanced through the deployment of neuropsychological assessment instruments, such as cognitive function scales and executive function tests, as well as sophisticated imaging modalities including structural and functional MRI and PET scans. These methodologies have enabled the delineation of specific cognitive domains affected by DM and have facilitated the correlation of these deficits with both structural and functional alterations in the brain. Finally, a range of prevention and treatment strategies for cognitive dysfunction in DM has been identified, involving stringent blood glucose regulation, blood pressure and lipid management, the utilization of antioxidants and anti-inflammatory therapies, neuroprotective agents, and psychological interventions. These strategies are designed to mitigate the risk factors and pathogenic processes that predispose diabetic patients to cognitive decline.

Despite substantial advancements, current research on cognitive dysfunction in DM confronts several challenges. A primary constraint is the diversity within study populations, which complicates the generalizability of research findings. Furthermore, the preponderance of cross-sectional and observational study designs constrains our ability to infer causality. Prospective longitudinal studies are essential to clarify the temporal sequence between DM, its associated complications, and the onset of cognitive impairment. The absence of standardized assessment tools tailored for cognitive dysfunction in DM also presents a significant barrier to comparative research. The research

community should focus on developing and validating such tools to ensure uniformity and dependability in cognitive evaluations. The intricate mechanisms underlying cognitive impairment in DM are not yet fully elucidated, necessitating further investigation to uncover the molecular and cellular pathways at play. Experimental research employing animal models and in vitro systems is poised to offer critical insights into these mechanisms. Moreover, while various preventive and therapeutic strategies have been proposed, there is an insufficient number of randomized controlled trials to substantiate their effectiveness. Future research should prioritize the conduct of clinical trials to ascertain the efficacy of these interventions and to pinpoint novel therapeutic targets.

The discoveries emanating from research on cognitive dysfunction in DM hold significant implications for clinical practice and policy formulation. Healthcare professionals should be vigilant to the heightened risk of cognitive impairment in diabetic patients and integrate routine cognitive evaluations into their clinical routines. Early identification of cognitive deficits has the potential to prompt timely interventions that may decelerate or even reverse the trajectory of impairment. In the realm of policy, there is a pressing need for guidelines that address the management of cognitive dysfunction in DM. These guidelines should advocate for a holistic approach that incorporates glucose control, management of vascular risk factors, and cognitive assessments as integral components of standard diabetes care. Additionally, there is a critical need for public health campaigns that encourage lifestyle modifications to prevent DM and its array of complications, including cognitive decline. Educational initiatives should be crafted to inform patients, caregivers, and healthcare providers about the association between DM and cognitive well-being.

In summation, the study of cognitive dysfunction in DM is a vibrant and evolving field. The collective findings to date lay the groundwork for continued research aimed at enhancing the quality of life for individuals with DM by safeguarding their cognitive function. Future research endeavors should strive to overcome current limitations and translate discoveries into actionable strategies for clinical application and health policy guidance.

ACKNOWLEDGEMENTS

The authors gratefully acknowledge the financial support from State Grid Corporation of China-Deepening research and application of PV Cloud (SGZJ0000KXJS1800281).

REFERENCES

[1] Zhou, B. et al. Worldwide trends in diabetes prevalence and treatment from 1990 to 2022: a pooled analysis of 1108 population-representative studies with 141 million participants. The Lancet 404, 2077–2093 (2024).

[2] Choi, Y. et al. Association of Cardiovascular Health Score With Early--and Later--Onset Diabetes and With Subsequent Vascular Complications of Diabetes. Journal of the American Heart Association 12, e027558 (2023).

[3] Li, R. et al. Correlation of mild cognitive impairment with the thickness of retinal nerve fiber layer and serum indicators in type 2 diabetic patients. Front. Endocrinol. 14, 1299206 (2024).

[4] Biessels, G. J. & Whitmer, R. A. Cognitive dysfunction in diabetes: how to implement emerging guidelines. Diabetologia 63, 3–9 (2020).

[5] Zhou, X. et al. Subcutaneous device-free islet transplantation. Front. Immunol. 14, 1287182 (2023).

[6] Chen, W., Cai, W., Hoover, B. & Kahn, C. R. Insulin Action in the Brain: Cell Types, Circuits, and Diseases. TrendsNeurosc 45, 384–400 (2023).

[7] Hölscher, C. Insulin Signaling Impairment in the Brain as a Risk Factor in Alzheimer's Disease. Front. Aging Neurosci. 11, 88 (2019).

[8] Lee, J. C., Kim, S. J., Hong, S. & Kim, Y. Diagnosis of Alzheimer's disease utilizing amyloid and tau as fluid biomarkers. Exp Mol Med 51, 1–10 (2019).

[9] González, P., Lozano, P., Ros, G. & Solano, F. Hyperglycemia and Oxidative Stress: An Integral, Updated and Critical Overview of Their Metabolic Interconnections. IJMS 24, 9352 (2023).

[10] Matuschik, L. et al. Hyperglycemia Induces Inflammatory Response of Human Macrophages to CD163-Mediated Scavenging of Hemoglobin-Haptoglobin Complexes. IJMS 23, 1385 (2022).

[11] Bayaraa, O. et al. Hyperglycemic conditions induce rapid cell dysfunction-promoting transcriptional alterations in human aortic endothelial cells. Sci Rep 12, 20912 (2022).

[12] Ogoh, S. Relationship between cognitive function and regulation of cerebral blood flow. J Physiol Sci 67, 345–351 (2017).

[13] Rungratanawanich, W., Qu, Y., Wang, X., Essa, M. M. & Song, B.-J. Advanced glycation end products (AGEs) and other adducts in aging-related diseases and alcohol-mediated tissue injury. Exp Mol Med 53, 168–188 (2021).

[14] Liberty, I. A. et al. The characteristics and risk of obesity central and concomitant impaired fasting glucose: Findings from a cross-sectional study. PLoS ONE 19, e0305604 (2024).

[15] Ottoy, J. et al. Association of short-term cognitive decline and MCI-to-AD dementia conversion with CSF, MRI, amyloid- and 18F-FDG-PET imaging. NeuroImage: Clinical 22, 101771 (2019).

[16] Yue, Q. & Hoi, M. P. M. Emerging roles of astrocytes in blood-brain barrier disruption upon amyloid-beta insults in Alzheimer's. NEURAL REGENERATION RESEARCH 18, 1890–1902 (2023).

[17] Yong, S. et al. The effect and mechanism of palmar ginseng in type 2 diabetic cognitive impairment. Heliyon 10, e32525 (2024).

[18] You, Y. et al. The prevalence of mild cognitive impairment in type 2 diabetes mellitus patients: a systematic review and meta-analysis. Acta Diabetol 58, 671–685 (2021).

[19] Aderinto, N. et al. The impact of diabetes in cognitive impairment: A review of current evidence and prospects for future investigations. Medicine 102, e35557 (2023).

[20] Dv, D. Blood pressure control for diabetic retinopathy (Review). Cochrane Database of Systematic Reviews 3, CD006127 (2023).

[21] Xue, M. et al. Diabetes mellitus and risks of cognitive impairment and dementia: A systematic review and meta-analysis of 144 prospective studies. Ageing Research Reviews 55, 1568–1637 (2019).

[22] Chawla, A., Chawla, R. & Jaggi, S. Microvasular and macrovascular complications in diabetes mellitus: Distinct or continuum? Indian J Endocr Metab 20, 546 (2016).

[23] Zhao, G. et al. Endothelial KLF11 is a novel protector against diabetic atherosclerosis. Cardiovascular Diabetology 23, 381 (2024).

[24] Bae, S.-G. et al. Single-cell transcriptome analysis of cavernous tissues reveals the key roles of pericytes in diabetic erectile dysfunction. eLife 12, RP88942 (2024).

[25] Nuthikattu, S., Milenkovic, D., Norman, J. E. & Villablanca, A. C. Single nuclei transcriptomics in diabetic mice reveals altered brain hippocampal endothelial cell function, permeability, and behavior. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 1870, 166970 (2024).

[26] Dutta, B. J. Inside the diabetic brain: Insulin resistance and molecular mechanism associated with cognitive impairment and its possible therapeutic strategies. Pharmacological Research 182, 106358 (2022).

[27] Ruisch, I. H. et al. Molecular landscape of the overlap between Alzheimer's disease and somatic insulin-related diseases. Alz Res Therapy 16, 239 (2024).

[28] Galizzi, G. & Carlo, M. D. Insulin and Its Key Role for Mitochondrial Function/Dysfunction and Quality Control: A Shared Link between Dysmetabolism and Neurodegeneration. biology 11, 943 (2022).

[29] Arjunan, A., Sah, D. K., Woo, M. & Song, J. Identification of the molecular mechanism of insulin-like growth factor-1 (IGF-1): a promising therapeutic target for neurodegenerative diseases associated with metabolic syndrome. Cell Biosci 13, 16 (2023).

[30] Bhatti, J. S. Oxidative stress in the pathophysiology of type 2 diabetes and related complications: Current therapeutics strategies and future perspectives. Free Radical Biology and Medicine 184, 114–134 (2022).

[31] Lennicke, C. Redox metabolism: ROS as specific molecular regulators of cell signaling and function. Molecular Cell 81, 3691–3707 (2021).

[32] Bhatt, S., Puli, L. & Patil, C. R. Role of reactive oxygen species in the progression of Alzheimer's disease. Drug Discovery Today 26, 794–803 (2021).

[33] Gonzalez, Y. High glucose concentrations induce TNF-α production through the down-regulation of CD33 in primary human monocytes. BMC Immunology 13, 19 (2012).

[34] Zhang, J. Advanced glycation end products initiate the mutual promoting cycle between centrosome amplification and the release of inflammatory cytokines in human vascular endothelial cells. Biochemical and Biophysical Research Communications 681, 232–241 (2023).

[35] Gillies, N. Interleukin-6 is associated with chronic hyperglycemia and insulin resistance in patients after acute pancreatitis. Pancreatology 16, 748–755 (2016).

[36] Nigdelioglu Dolanbay, S., Şirin, S. & Aslim, B. Allocryptopine Attenuates Inflammatory Responses in Microglial Cells Via TLR4-Dependent NF-κB and p38 MAPK Pathways. Mol Neurobiol (2024) doi:10.1007/s12035-024-04520-x.

[37] Ungvari, Z. et al. Hypertension-induced cognitive impairment: from pathophysiology to public health. Nat Rev Nephrol 17, 639–654 (2021).

[38] Yang, D.-R., Wang, M.-Y., Zhang, C.-L. & Wang, Y. Endothelial dysfunction in vascular complications of diabetes: a comprehensive review of mechanisms and implications. Front. Endocrinol. 15, 1359255 (2024).

[39] Zha, F. et al. Non-linear relationship between lipid accumulation products and risk of diabetes in Japanese adults. Sci Rep 14, 27106 (2024).

[40] Liu, L. et al. The Intersection of cerebral cholesterol metabolism and Alzheimer's disease: Mechanisms and therapeutic prospects. Heliyon 10, e30523 (2024).

[41] Ha, J. et al. Relationship Between Adipokines, Cognition, and Brain Structures in Old Age Depending on Obesity. The Journals of Gerontology: Series A 78, 120–128 (2023).

[42] Santiago, J. A. Physical activity and lifestyle modifications in the treatment of neurodegenerative diseases. Frontiers in Aging Neuroscience 15, 1185671 (2023).

[43] Román, G. C., Jackson, R. E., Gadhia, R., Román, A. N. & Reis, J. Mediterranean diet: The role of long-chain ω-3 fatty acids in fish; polyphenols in fruits, vegetables, cereals, coffee, tea, cacao and wine; probiotics and vitamins in prevention of stroke, age-related cognitive decline, and Alzheimer disease. Revue Neurologique 175, 724–741 (2019).

[44] Li, J. et al. Therapeutic potential of Lingjiao Gouteng decoction in acute alcohol intoxication and alcohol-induced brain injury involving the RhoA/ROCK2/NF-κB signaling pathway. Journal of Ethnopharmacology 328, 118114 (2024).

[45] Trento, M. et al. Depression, anxiety, cognitive impairment and their association with clinical and demographic variables in people with type 2 diabetes: a 4-year prospective study. J Endocrinol Invest 37, 79–85 (2014).

[46] Ahmad, M. H., Rizvi, M. A., Fatima, M. & Mondal, A. C. Pathophysiological implications of neuroinflammation mediated HPA axis dysregulation in the prognosis of cancer and depression. Molecular and Cellular Endocrinology 520, 111093 (2021).

[47] Ren, Y. et al. The impact of loneliness and social isolation on the development of cognitive decline and Alzheimer's Disease. Frontiers in Neuroendocrinology 69, 101061 (2023).

[48] Seaquist, E. R. et al. Effect of thiazolidinediones and insulin on cognitive outcomes in ACCORD-MIND. Journal of Diabetes and its Complications 27, 485–491 (2013).

[49] Wu, C.-Y. et al. Glucose-lowering drugs, cognition, and dementia: The clinical evidence. Neuroscience & Biobehavioral Reviews 137, 104654 (2022).

[50] Wu, C. et al. Relationships between memory decline and the use of metformin or DPP4 inhibitors in people with type 2 diabetes with normal cognition or Alzheimer's disease, and the role APOE carrier status. Alzheimer's & Dementia 16, 1663–1673 (2020).

[51] Meng, J. et al. Dipeptidyl peptidase-4 inhibitors alleviate cognitive dysfunction in type 2 diabetes mellitus. Lipids Health Dis 22, 219 (2023).

[52] Šimonienė, D. & Veličkienė, D. Relation between Exogenous Insulin and Cognitive Function in Type 2 Diabetes Mellitus. Medicina 57, 943 (2021).

[53] Alagiakrishnan, K., Zhao, N., Mereu, L., Senior, P. & Senthilselvan, A. Montreal Cognitive Assessment Is Superior to Standardized Mini-Mental Status Exam in Detecting Mild Cognitive Impairment in the Middle-Aged and Elderly Patients with Type 2 Diabetes Mellitus. BioMed Research International 2013, 1–5 (2013).

[54] Faaitiiti, K. L. & Jupiter, D. C. Diabetes-Specific Dementia: A Structured Literature Review of Cognitive Assessment Methods. The Journal of Foot and Ankle Surgery 61, 401–409 (2022).

[55] Jiang, J. et al. Prolactin deficiency drives diabetes- associated cognitive dysfunction by inducing microglia-mediated synaptic loss. (2024).

[56] Fu, L. et al. Altered Dynamics of Brain Spontaneous Activity and Functional Networks Associated With Cognitive Impairment in Patients With Type 2 Diabetes. Magnetic Resonance Imaging 60, 2547–2561 (2024).

[57] Blázquez, E. et al. Significance of Brain Glucose Hypometabolism, Altered Insulin Signal Transduction, and Insulin Resistance in Several Neurological Diseases. Front. Endocrinol. 13, 873301 (2022).

[58] Ioannou, K. et al. Tau PET positivity predicts clinically relevant cognitive decline driven by Alzheimer's disease compared to comorbid cases; proof of concept in the ADNI study. Mol Psychiatry (2024) doi:10.1038/s41380-024-02672-9.

[59] Sampath Kumar, A. et al. Exercise and insulin resistance in type 2 diabetes mellitus: A systematic review and meta-analysis. Annals of Physical and Rehabilitation Medicine 62, 98–103 (2019).

[60] Bai, X. et al. Aerobic Exercise Combination Intervention to Improve Physical Performance Among the Elderly: A Systematic Review. Front. Physiol. 12, 798068 (2022).

[61] Sue, R.-V. Effect of the Mediterranean diet on cognition and brain morphology and function: a systematic review of randomized controlled trials. Am J Clin Nutr 107, 389–404 (2018).

[62] Lin, K.-J. et al. Two Birds One Stone: The Neuroprotective Effect of Antidiabetic Agents on Parkinson Disease—Focus on Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors. Antioxidants 10, 1935 (2021).

[63] Brown, E., Heerspink, H. J. L., Cuthbertson, D. J. & Wilding, J. P. H. SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications. The Lancet 398, 262–276 (2021).

[64] Abraham, H. M. A., White, C. M. & White, W. B. The Comparative Efficacy and Safety of the Angiotensin Receptor Blockers in the Management of Hypertension and Other Cardiovascular Diseases. Drug Saf 38, 33–54 (2015).

[65] Wang, W. & Li, X. Cognitive function in dyslipidemia patients: exploring the impact of statins. Front. Neurol. 15, 1436010 (2024).

[66] Superti, F. & Russo, R. Alpha-Lipoic Acid: Biological Mechanisms and Health Benefits. Antioxidants 13, 1228 (2024).

[67] Jiang, J. et al. Antioxidants and the risk of sleep disorders: results from NHANES and two-sample Mendelian randomization study. Front. Nutr. 11, 1453064 (2024).

[68] Martucci, A. & Nucci, C. Evidence on neuroprotective properties of coenzyme Q10 in the treatment of glaucoma. Neural Regen Res 14, 197 (2019).

[69] Pescador Jimenez, M. et al. Midlife Residential Greenness and Late-Life Cognitive Decline among Nurses' Health Study Participants. Environ Health Perspect 132, 077003 (2024).

[70] Secnik, J. et al. Cholinesterase inhibitors in patients with diabetes mellitus and dementia: an open-cohort study of ~23 000 patients from the Swedish Dementia Registry. BMJ Open Diab Res Care 8, e000833 (2020).

[71] Congdon, E. E., Ji, C., Tetlow, A. M., Jiang, Y. & Sigurdsson, E. M. Tau-targeting therapies for Alzheimer disease: current status and future directions. Nat Rev Neurol 19, 715–736 (2023).